{
  "gene": "CYP2D6",
  "analysis_method": "DeepSeek API with RAG",
  "existing_diseases_count": 0,
  "existing_diseases": [],
  "pubmed_context_available": true,
  "pubmed_context_length": 4599,
  "query": "\nYou are a genetics expert. Analyze the CYP2D6 gene comprehensively using ONLY the provided literature context.\n\n\n**IMPORTANT: Base your analysis STRICTLY on the provided PubMed literature context below. Do NOT hallucinate or make up information not supported by the literature.**\n\n**Retrieved PubMed Literature Context:**\nthis review identified 5 inducers, 53 strong/moderate inhibitors, and 32 \nmajor/intermediate substrates of CYP2C8. Typical examples were illustrated to \npredict DDIs by in vitro-in vivo extrapolation. The factors influencing DDI \nmagnitude include genetic polymorphisms (CYP2C8, SLCO1B1, \nUDP-glucuronosyltransferase, and pregnane X receptor), hepatic and renal \nfunction, properties of CYP2C8 perpetrators (dose, treatment course, systemic \nconcentrations, time after discontinuation, inhibitory potency, inhibitory \nabilities of metabolites on CYP2C8), properties of object drugs (whether the \nactive metabolite of object drug is a CYP2C8 substrate, therapeutic index, \nstereoselectivity), differences in DDI risk for drugs from similar therapeutic \nclasses, and whether multiple interaction mechanisms are involved. Some \nbotanical supplements showed potential to influence CYP2C8 in vitro or in animal \nexperiments.\nCONCLUSION: CYP2C8 is an important but underrecognized DME. This article\n\n---\n\nBACKGROUND AND HYPOTHESIS: The US Food and Drug Administration (FDA) package \ninsert for clozapine states that cytochrome P450 (CYP) 2D6 is important in \nclozapine metabolism, implying that CYP2D6 genotypes should be considered in \nclozapine dosing. We investigated differences for clozapine \nconcentration-to-dose (C/D) ratios, as a pharmacokinetic measure, in relation to \nCYP2D6 phenotype.\nSTUDY DESIGN: Linear mixed-effect regression models were applied to investigate \nthe association between genotype-predicted CYP2D6 metabolizer phenotypes and C/D \nratios including the effects of age, sex, smoking, and sampling time in a pooled \nsample of three cohorts, both without and with adjusting for the interaction \nbetween cohort and CYP2D6 phenotype, as well as in separate models stratified by \ncohort.\nSTUDY RESULTS: We included 897 patients from three cohorts with a total of \n10 428 clozapine and norclozapine measurements. We found no association between\n\n---\n\n# PubMed Search Results for: CYP2D6\n# Found 5 articles\n# ==================================================\n\n1. Drug Des Devel Ther. 2025 Sep 16;19:8391-8413. doi: 10.2147/DDDT.S541536. \neCollection 2025.\n\nCYP2C8-Mediated Drug-Drug Interactions and the Factors Influencing the \nInteraction Magnitude.\n\nZhu LL(#)(1), Yu LY(#)(2), Wang YH(2), Zhou Q(2).\n\nAuthor information:\n(1)VIP Care and Geriatric Ward, Division of Nursing, The Second Affiliated \nHospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, \nPeople's Republic of China.\n(2)Department of Pharmacy, The Second Affiliated Hospital, School of Medicine, \nZhejiang University, Hangzhou, Zhejiang Province, People's Republic of China.\n(#)Contributed equally\n\n---\n\nBACKGROUND: Older adults often have multiple morbidities that may lead to \npolypharmacy. Cytochrome P450 (CYP) 2C8 has shown significant contributions in \nthe metabolism of various medications; however, its related drug-drug \ninteractions (DDIs) appear to be underrecognized in clinical practice compared \nto the major CYP enzymes (eg, CYP3A4, CYP2D6). This review summarizes the \nprogress of CYP2C8-mediated DDIs and factors influencing the interaction \nmagnitude.\nMETHODS: Using CYP2C8 and drug interactions as the search terms, literature was \nsearched through PubMed, Web of Science, and Embase as of January 2025. Eligible \nstudies were identified following PRISMA guidelines. Screening and inclusion \nwere assessed by two independent reviewers and 57 studies met \ninclusion/exclusion criteria.\nRESULTS: Based on authoritative sources (FDA, EMA, DrugBank), and literature, \nthis review identified 5 inducers, 53 strong/moderate inhibitors, and 32\n\n---\n\n10 428 clozapine and norclozapine measurements. We found no association between \nCYP2D6 phenotypes and clozapine or norclozapine C/D ratios or \nclozapine-to-norclozapine ratios in the pooled sample with or without adjustment \nfor the interaction between cohort and CYP2D6 phenotype nor when analyzing three \ncohorts separately (P>.05 in all cases). Older patients and females had higher \nC/D ratios of clozapine and norclozapine (P<.001, P<.001, P<.001 and P=.02), \nwhereas smokers had lower C/D ratios of clozapine and norclozapine as well as \nclozapine-to-norclozapine ratios (P<.001 for all three).\nCONCLUSIONS: We reported no association between CYP2D6 genotype-predicted \nphenotypes and clozapine pharmacokinetics. Dose adjustment based on CYP2D6 \ngenotyping is unlikely to be helpful in managing clozapine-treated patients. We \npropose that the current FDA package insert should be updated to avoid \nmisleading prescribers.\n\n\n\n**Analysis requested (base ONLY on provided literature):**\n\n1. **Molecular Function & Structure**:\n   - What is CYP2D6's primary molecular function according to the literature?\n   - What protein domains does it contain?\n   - How does it regulate cellular processes?\n\n2. **Disease Mechanisms**:\n   - How do CYP2D6 mutations cause disease based on the studies?\n   - What are the key pathogenic mechanisms described?\n   - Are there genotype-phenotype correlations mentioned?\n\n3. **Clinical Phenotypes**:\n   - What clinical features are described in the literature?\n   - How do different mutation types affect phenotype?\n   - What inheritance patterns are reported?\n\n4. **Research Findings**:\n   - What are the key discoveries about CYP2D6 in the literature?\n   - Any disease associations mentioned?\n   - Therapeutic approaches discussed?\n\n5. **Literature Limitations**:\n   - What aspects of CYP2D6 are NOT covered in the provided context?\n   - What additional research is needed?\n\n**CRITICAL: Only cite information that is explicitly mentioned in the provided PubMed context. If information is not available in the context, clearly state this limitation.**\n",
  "analysis": "Based strictly on the provided PubMed literature context, here is a comprehensive analysis of the CYP2D6 gene:\n\n### 1. Molecular Function & Structure\n- **Primary Molecular Function**: The literature explicitly identifies CYP2D6 as a cytochrome P450 enzyme involved in drug metabolism. Specifically, it is stated as being \"important in clozapine metabolism.\"\n- **Protein Domains**: The provided literature does not describe any specific protein domains of CYP2D6.\n- **Cellular Process Regulation**: No information is provided on how CYP2D6 regulates cellular processes beyond its role in metabolizing the drug clozapine.\n\n### 2. Disease Mechanisms\n- **Mutations and Disease Causation**: The literature does not describe how CYP2D6 mutations cause disease or any specific pathogenic mechanisms.\n- **Genotype-Phenotype Correlations**: The context discusses \"CYP2D6 genotype-predicted phenotypes\" in relation to clozapine pharmacokinetics but does not detail specific mutations or their correlations with disease phenotypes. The study found no association between these phenotypes and clozapine concentration-to-dose ratios.\n\n### 3. Clinical Phenotypes\n- **Clinical Features**: No clinical features related to CYP2D6 mutations or deficiencies are described in the provided context.\n- **Effect of Mutation Types**: The literature does not discuss how different types of mutations (e.g., missense, nonsense) affect phenotype.\n- **Inheritance Patterns**: No inheritance patterns for CYP2D6-related traits or disorders are mentioned.\n\n### 4. Research Findings\n- **Key Discoveries**: The primary finding is that there is \"no association between CYP2D6 phenotypes and clozapine or norclozapine C/D ratios or clozapine-to-norclozapine ratios\" in a study of 897 patients. This challenges the FDA package insert's implication that CYP2D6 genotyping should guide clozapine dosing.\n- **Disease Associations**: No disease associations are mentioned; the focus is solely on clozapine pharmacokinetics.\n- **Therapeutic Approaches**: The literature suggests that \"dose adjustment based on CYP2D6 genotyping is unlikely to be helpful in managing clozapine-treated patients\" and proposes updating the FDA package insert to avoid misleading prescribers. No other therapeutic strategies are discussed.\n\n### 5. Literature Limitations\n- **Aspects Not Covered**: The provided context is extremely limited and does not cover:\n  - The structure, domains, or detailed molecular mechanisms of CYP2D6.\n  - How CYP2D6 mutations lead to diseases or specific pathogenic pathways.\n  - Clinical phenotypes, inheritance patterns, or effects of mutation types.\n  - Broader roles of CYP2D6 in metabolizing other drugs or endogenous compounds.\n  - Any disease associations beyond the pharmacokinetics of clozapine.\n  - Therapeutic approaches other than the recommendation against CYP2D6-guided dosing for clozapine.\n- **Additional Research Needed**: Based on the context, further research is implied to validate the lack of association between CYP2D6 phenotypes and clozapine dosing in diverse populations and to update regulatory guidelines accordingly. The literature does not specify other research gaps.\n\n**Note**: This analysis is constrained by the narrow scope of the provided literature, which focuses exclusively on CYP2D6's role in clozapine metabolism and does not address its broader genetic, structural, or clinical characteristics.",
  "timestamp": "2025-10-01 15:59:40"
}